These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 16000578

  • 1. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
    Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, U P, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ.
    Clin Cancer Res; 2005 Jul 01; 11(13):4810-7. PubMed ID: 16000578
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM.
    Clin Cancer Res; 2005 Jul 01; 11(13):4818-26. PubMed ID: 16000579
    [Abstract] [Full Text] [Related]

  • 3. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.
    Clin Cancer Res; 2003 May 01; 9(5):1639-47. PubMed ID: 12738716
    [Abstract] [Full Text] [Related]

  • 4. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
    Welt S, Ritter G, Williams C, Cohen LS, Jungbluth A, Richards EA, Old LJ, Kemeny NE.
    Clin Cancer Res; 2003 Apr 01; 9(4):1347-53. PubMed ID: 12684403
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
    Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A.
    Nucl Med Biol; 2006 Nov 01; 33(8):991-8. PubMed ID: 17127172
    [Abstract] [Full Text] [Related]

  • 6. Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
    Herbertson RA, Tebbutt NC, Lee FT, Gill S, Chappell B, Cavicchiolo T, Saunder T, O'Keefe GJ, Poon A, Lee ST, Murphy R, Hopkins W, Scott FE, Scott AM.
    J Nucl Med; 2014 Apr 01; 55(4):534-9. PubMed ID: 24556590
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of anticolon cancer humanized antibody A33.
    Welt S, Ritter G, Williams C, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE.
    Clin Cancer Res; 2003 Apr 01; 9(4):1338-46. PubMed ID: 12684402
    [Abstract] [Full Text] [Related]

  • 8. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.
    Sakamoto J, Oriuchi N, Mochiki E, Asao T, Scott AM, Hoffman EW, Jungbluth AA, Matsui T, Lee FT, Papenfuss A, Kuwano H, Takahashi T, Endo K, Old LJ.
    Cancer Sci; 2006 Nov 01; 97(11):1248-54. PubMed ID: 17034367
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A, Stafford N, Rowlinson-Busza G, Stewart JS, Epenetos AA.
    Cancer Res; 1995 Mar 01; 55(5):1060-9. PubMed ID: 7866989
    [Abstract] [Full Text] [Related]

  • 10. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
    Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, Alavi A, Losman MJ, Brenner A, Goldenberg DM.
    Clin Colorectal Cancer; 2002 May 01; 2(1):31-42. PubMed ID: 12453334
    [Abstract] [Full Text] [Related]

  • 11. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
    Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA.
    Clin Cancer Res; 2004 Aug 01; 10(15):5014-21. PubMed ID: 15297402
    [Abstract] [Full Text] [Related]

  • 12. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [Abstract] [Full Text] [Related]

  • 13. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors.
    Delaloye AB, Delaloye B, Buchegger F, Vogel CA, Gillet M, Mach JP, Smith A, Schubiger PA.
    J Nucl Med; 1997 Jun 01; 38(6):847-53. PubMed ID: 9189128
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer.
    Ward RL, Packham D, Smythe AM, Murray J, Anderson-Stewart P, Kitchen N, Muirhead R, Phillips P, Gray P, Bigg-Wither G, Prabakaran K, Freund J, Fullham M, Rule M, Dalley D, Meagher A, Hawkins NJ, Smith GM.
    Clin Cancer Res; 2000 Dec 01; 6(12):4674-83. PubMed ID: 11156219
    [Abstract] [Full Text] [Related]

  • 15. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.
    Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, Smyth FE, Welt S, Old LJ, Scott AM.
    J Nucl Med; 2001 May 01; 42(5):764-9. PubMed ID: 11337573
    [Abstract] [Full Text] [Related]

  • 16. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Mar 01; 38(3):409-18. PubMed ID: 9074529
    [Abstract] [Full Text] [Related]

  • 17. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM.
    J Nucl Med; 2005 Apr 01; 46(4):620-33. PubMed ID: 15809485
    [Abstract] [Full Text] [Related]

  • 18. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.
    Infante JR, Bendell JC, Goff LW, Jones SF, Chan E, Sudo T, Burris HA, Berlin JD.
    Eur J Cancer; 2013 Apr 01; 49(6):1169-75. PubMed ID: 23294608
    [Abstract] [Full Text] [Related]

  • 19. (124)I-huA33 antibody PET of colorectal cancer.
    Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM.
    J Nucl Med; 2011 Aug 01; 52(8):1173-80. PubMed ID: 21764796
    [Abstract] [Full Text] [Related]

  • 20. Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells.
    Cortez C, Tomaskovic-Crook E, Johnston AP, Scott AM, Nice EC, Heath JK, Caruso F.
    ACS Nano; 2007 Sep 01; 1(2):93-102. PubMed ID: 19206525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.